{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:48:34Z","timestamp":1791881314808,"version":"4.3.4"},"reference-count":117,"publisher":"ALTEX Edition","issue":"4","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ALTEX"],"abstract":"<jats:p>Vaccines are administered to large populations of healthy individuals, including vulnerable groups, making an exceptionally rigorous safety profile a prerequisite for their approval and use. Nonclinical vaccine safety assessment has traditionally relied on standardized animal testing methodologies, which face increasing challenges: the ethical imperative to reduce animal use, the need for faster vaccine development, and the limitations of animal models in predicting human-specific immune responses. The advent of modern vaccine platforms such as mRNA technologies and viral-vector vaccines necessitates a re-evaluation of safety frameworks. This article explores emerging strat\u00adegies to modernize vaccine safety assessment, integrating new approach methodologies (NAMs), including in vitro systems, artificial intelligence, and adverse outcome pathways (AOPs). Ethical refinements to animal husbandry practices, including group housing, humane endpoints, pain man\u00adagement and scaled blood sampling volumes, are also discussed to align with the principles of the 3Rs (replacement, reduction, refinement). The adoption of molecular and omics-based techniques, along with innovative validation strategies, offers opportunities to improve predictive accuracy and mechanistic insight. The article highlights a strategic framework for implementing NAMs across the three stages at which animals are still used \u2013 early screening, late nonclinical development, and batch release \u2013 while ensuring alignment with regulatory requirements. Implementation must be careful enough to ensure that the use of NAMs in the safety evaluation of vaccines maintains or exceeds current safety assessment standards. By addressing scientific, ethical, and regulatory challenges, NAMs have the potential to transform vaccine safety assessment, enhancing human relevance and accelerating innovation in vaccine development. \nPlain language summaryThis article examines the evolving landscape of vaccine safety assessment, focusing on opportunities to modernize testing approaches through new approach methodologies (NAMs). Drawing on recent discussions with stakeholders across industry, academia, and regulatory bodies, we outline key chal\u00adlenges and strategic pathways for implementing NAMs in vaccine development while maintaining robust safety standards. Special attention is given to emerging technologies, such as human-relevant test systems, artificial intelligence, and virtual control groups, to the replacement of animal-based potency, pyrogen and adventitious agent tests used for batch release, and to considerations for regu\u00adlatory acceptance and implementation strategies.<\/jats:p>","DOI":"10.14573\/altex.2608271","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:05:19Z","timestamp":1791878719000},"page":"559-581","source":"Crossref","is-referenced-by-count":0,"title":["A roadmap for modernizing vaccine safety assessment: Challenges and opportunities for new approach methodologies"],"prefix":"10.14573","volume":"43","author":[{"given":"Fenna","family":"Sill\u00e9","sequence":"first","affiliation":[{"name":"Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-8928","authenticated-orcid":true,"given":"Paul","family":"Desert","sequence":"additional","affiliation":[{"name":"Sanofi Vaccine R&D, Marcy-l\u2019\u00c9toile, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Levis","sequence":"additional","affiliation":[{"name":"Food and Drug Administration \/ Center for Biologics Evaluation and Research \/ Office of Vaccines Research and Review (FDA\/CBER\/OVRR), Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0860-495X","authenticated-orcid":true,"given":"Claudia","family":"Wrzesinski","sequence":"additional","affiliation":[{"name":"Food and Drug Administration \/ Center for Biologics Evaluation and Research \/ Office of Vaccines Research and Review (FDA\/CBER\/OVRR), Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8246-755X","authenticated-orcid":true,"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hartung","sequence":"additional","affiliation":[{"name":"Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, MD, USA; CAAT-Europe, University of Konstanz, Konstanz, Germany; Johns Hopkins University, Doerenkamp-Zbinden Chair for Evidence-based Toxicology, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5675","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"68846","doi-asserted-by":"crossref","unstructured":"Abdel-Haq, H. (2024). Feasibility of using a type I IFN-based non-animal approach to predict vaccine efficacy and safety profiles. Vaccines 12, 583. doi:10.3390\/vaccines12060583","DOI":"10.3390\/vaccines12060583"},{"key":"68847","doi-asserted-by":"crossref","unstructured":"Afanasyeva, T. A. V., de Albuquerque, B. F. M., Doodeman, P. et al. (2025). Identifying pyrogenic contaminants using transcriptomic profiling of monocyte activation test with machine learning. bioRxiv, 2025.08.13.670109. doi:10.1101\/2025.08.13.670109","DOI":"10.1101\/2025.08.13.670109"},{"key":"68848","doi-asserted-by":"crossref","unstructured":"Bailey, M., Christoforidou, Z. and Lewis, M. C. (2013). The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants. Vet Immunol Immunopathol 152, 13-19. doi:10.1016\/j.vetimm.2012.09.022","DOI":"10.1016\/j.vetimm.2012.09.022"},{"key":"68849","doi-asserted-by":"crossref","unstructured":"Baral, P., Udit, S. and Chiu, I. M. (2019). Pain and immunity: Implications for host defence. Nat Rev Immunol 19, 433-447. doi:10.1038\/s41577-019-0147-2","DOI":"10.1038\/s41577-019-0147-2"},{"key":"68850","doi-asserted-by":"crossref","unstructured":"Benam, K. H., Villenave, R., Lucchesi, C. et al. (2016). Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 13, 151-157. doi:10.1038\/nmeth.3697","DOI":"10.1038\/nmeth.3697"},{"key":"68851","doi-asserted-by":"crossref","unstructured":"Bjornson-Hooper, Z. B., Fragiadakis, G. K., Spitzer, M. H. et al. (2022). A comprehensive atlas of immunological differences between humans, mice, and non-human primates. Front Immunol 13, 867015. doi:10.3389\/fimmu.2022.867015","DOI":"10.3389\/fimmu.2022.867015"},{"key":"68852","doi-asserted-by":"crossref","unstructured":"Bozkurt, B., Kamat, I. and Hotez, P. J. (2021). Myocarditis with COVID-19 mRNA vaccines. Circulation 144, 471-484. doi:10.1161\/circulationaha.121.056135","DOI":"10.1161\/CIRCULATIONAHA.121.056135"},{"key":"68853","doi-asserted-by":"crossref","unstructured":"Bruysters, M. W. P., Schiffelers, M.-J., Hoonakker, M. et al. (2017). Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop. Biologicals 48, 1-5. doi:10.1016\/j.biologicals.2017.06.006","DOI":"10.1016\/j.biologicals.2017.06.006"},{"key":"68854","doi-asserted-by":"crossref","unstructured":"Bryant, C. E. and Monie, T. P. (2012). Mice, men and the relatives: Cross-species studies underpin innate immunity. Open Biol 2, 120015. doi:10.1098\/rsob.120015","DOI":"10.1098\/rsob.120015"},{"key":"68855","doi-asserted-by":"crossref","unstructured":"Burgmaier, L., van den Berg, J., Gajewi, M. et al. (2025). Validation of the monocyte activation test demonstrating equivalence to the rabbit pyrogen test. Int J Mol Sci 26, 11136. doi:10.3390\/ijms262211136","DOI":"10.3390\/ijms262211136"},{"key":"68856","doi-asserted-by":"crossref","unstructured":"Busquet, F., Hartung, T., Pallocca, G. et al. (2020). Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines. Arch Toxicol 94, 2263-2272. doi:10.1007\/s00204-020-02787-2","DOI":"10.1007\/s00204-020-02787-2"},{"key":"68857","doi-asserted-by":"crossref","unstructured":"Carson, D., Myhill, S., Palmieri, E. et al. (2021). Development of a monocyte activation test as an alternative to the rabbit pyrogen test for mono- and multi-component shigella GMMA-based vaccines. Microorganisms 9, 1375. doi:10.3390\/microorganisms9071375","DOI":"10.3390\/microorganisms9071375"},{"key":"68858","doi-asserted-by":"crossref","unstructured":"Chabaud-Riou, M., Moreno, N., Guinchard, F. et al. (2017). G-protein based ELISA as a potency test for rabies vaccines. Biologicals 46, 124-129. doi:10.1016\/j.biologicals.2017.02.002","DOI":"10.1016\/j.biologicals.2017.02.002"},{"key":"68859","doi-asserted-by":"crossref","unstructured":"Charlebois, R. L., Sathiamoorthy, S., Logvinoff, C. et al. (2020). Sensitivity and breadth of detection of high-throughput sequencing for adventitious virus detection. NPJ Vaccines 5, 61. doi:10.1038\/s41541-020-0207-4","DOI":"10.1038\/s41541-020-0207-4"},{"key":"68860","doi-asserted-by":"crossref","unstructured":"Chiarot, E. and Pizza, M. (2022). Animal models in vaccinology: State of the art and future perspectives for an animal-free approach. Curr Opin Microbiol 66, 46-55. doi:10.1016\/j.mib.2021.11.014","DOI":"10.1016\/j.mib.2021.11.014"},{"key":"68861","doi-asserted-by":"crossref","unstructured":"Daniels, R., Van der Elst, W., Dieltjens, N. et al. (2022). Validation of the monocyte activation test with three therapeutic monoclonal antibodies. ALTEX 39, 621-635. doi:10.14573\/altex.2111301","DOI":"10.14573\/altex.2111301"},{"key":"68862","doi-asserted-by":"crossref","unstructured":"Destexhe, E., Prinsen, M. K., van Sch\u00f6ll, I. et al. (2013). Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. J Pharmacol Toxicol Methods 68, 367-373. doi:10.1016\/j.vascn.2013.04.003","DOI":"10.1016\/j.vascn.2013.04.003"},{"key":"68863","doi-asserted-by":"crossref","unstructured":"Destexhe, E. (2025). A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines 10, 192. doi:10.1038\/s41541-025-01245-3","DOI":"10.1038\/s41541-025-01245-3"},{"key":"68864","doi-asserted-by":"crossref","unstructured":"Dierick, J.-F., Halder, M., Jungbaeck, C. et al. (2022). The consistency approach for the substitution of in vivo testing for the quality control of established vaccines: Practical considerations and progressive vision. Open Res Eur 2, 116. doi:10.12688\/openreseurope.15077.2","DOI":"10.12688\/openreseurope.15077.2"},{"key":"68865","doi-asserted-by":"crossref","unstructured":"Dodd, C., Andrews, N., Petousis-Harris, H. et al. (2021). Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. BMJ Glob Health 6, Suppl 2, e003540. doi:10.1136\/bmjgh-2020-003540","DOI":"10.1136\/bmjgh-2020-003540"},{"key":"68866","doi-asserted-by":"crossref","unstructured":"Dozier, S., Brown, J. and Currie, A. (2011). Bridging the gap between validation and implementation of non-animal veterinary vaccine potency testing methods. Animals 1, 414-432. doi:10.3390\/ani1040414","DOI":"10.3390\/ani1040414"},{"key":"68867","unstructured":"EDQM (2020). Recombinant factor C: New Ph. Eur. chapter available as of 1 July 2020. European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France, 01 July 2020."},{"key":"68868","unstructured":"EDQM (2024a). BINACLE (Binding and Cleavage) Assay for Tetanus Neurotoxin: Outcomes of BSP136 Collaborative Study. European Directorate for the Quality of Medicines & HealthCare (Biological Standardisation Programme), Strasbourg. https:\/\/www.edqm.eu\/documents\/52006\/1583470\/BINACLE%20Assay%20for%20tetanus%20neurotoxin%20outcomes%20of%20project%20BSP136%2012\/68bb1cce-387b-2c21-1598-77a94a4440cd?t=1743176421330"},{"key":"68869","unstructured":"EDQM (2024b). European Pharmacopoeia bids adieu to the rabbit pyrogen test in its monographs. European Directorate for the Quality of Medicines & HealthCare, press release, Strasbourg, 5 July 2024. https:\/\/www.edqm.eu\/en\/-\/ph.-eur.-bids-adieu-to-rabbit-pyrogen-test-in-its-monographs"},{"key":"68870","unstructured":"EDQM (2026). Biological Standardisation Programme work programme: Validation of a rabies in vitro potency assay (reporting phase). European Directorate for the Quality of Medicines & HealthCare, Strasbourg. https:\/\/www.edqm.eu\/en\/bsp-work-programme"},{"key":"68871","doi-asserted-by":"crossref","unstructured":"El Arab, R. A., Alkhunaizi, M., Alhashem, Y. N. et al. (2025). Artificial intelligence in vaccine research and development: An umbrella review. Front Immunol 16, 1567116. doi:10.3389\/fimmu.2025.1567116","DOI":"10.3389\/fimmu.2025.1567116"},{"key":"68872","unstructured":"EMA (1997). Note for Guidance on Preclinical Pharmacological and Toxicological Testing of Vaccines (CPMP\/SWP\/465\/95). European Medicines Agency (then EMEA\/CPMP), London. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-preclinical-pharmacological-and-toxicological-testing-vaccines_en.pdf"},{"key":"68873","unstructured":"EMA (2016). Questions and answers on the withdrawal of the Note for Guidance on preclinical pharmacological and toxicological testing of vaccines (EMA\/CHMP\/SWP\/242917\/2016). European Medicines Agency, London. https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-and-answers-withdrawal-cpmp-note-guidance-preclinical-pharmacological-and-toxicological-testing-vaccines-cpmpswp465_en.pdf"},{"key":"68874","unstructured":"EMA (2025). Reflection paper on lessons learned from the COVID-19 pandemic: Scientific considerations on non-clinical aspects. Draft (consultation version, 10 June 2025). European Medicines Agency, Amsterdam. EMA\/CHMP\/55697\/2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-lessons-learned-covid-19-pandemic-scientific-considerations-non-clinical-aspects_en.pdf"},{"key":"68875","unstructured":"FDA (2006). Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications. Guidance for Industry, February 2006. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD."},{"key":"68876","unstructured":"FDA (2026). Pyrogen and Endotoxins Testing: Questions and Answers. Guidance for Industry, Edition 2, March 2026. U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"68877","doi-asserted-by":"crossref","unstructured":"Ferreira, G. S., Veening-Griffioen, D. H., Boon, W. P. C. et al. (2020). Levelling the translational gap for animal to human efficacy data. Animals 10, 1199. doi:10.3390\/ani10071199","DOI":"10.3390\/ani10071199"},{"key":"68878","doi-asserted-by":"crossref","unstructured":"Gerdts, V., Wilson, H. L., Meurens, F. et al. (2015). Large animal models for vaccine development and testing. ILAR J 56, 53-62. doi:10.1093\/ilar\/ilv009","DOI":"10.1093\/ilar\/ilv009"},{"key":"68879","doi-asserted-by":"crossref","unstructured":"Golden, E., Allen, D., Amberg, A. et al. (2024). Toward implementing virtual control groups in nonclinical safety studies: Workshop report and roadmap to implementation. ALTEX 41, 282-301. doi:10.14573\/altex.2310041","DOI":"10.14573\/altex.2310041"},{"key":"68880","doi-asserted-by":"crossref","unstructured":"Goyal, G., Prabhala, P., Mahajan, G. et al. (2022). Ectopic lymphoid follicle formation and human seasonal influenza vaccination responses recapitulated in an organ-on-a-chip. Adv Sci 9, 2103241. doi:10.1002\/advs.202103241","DOI":"10.1002\/advs.202270090"},{"key":"68881","doi-asserted-by":"crossref","unstructured":"Greinacher, A., Thiele, T., Warkentin, T. E. et al. (2021). Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384, 2092-2101. doi:10.1056\/NEJMoa2104840","DOI":"10.1056\/NEJMoa2104840"},{"key":"68882","unstructured":"Hansell, L. and Hartung, T. (2025). Roadmap to reduce animal testing \u2013 The EU talks, the US acts! Frontiers Policy Lab. https:\/\/policylabs.frontiersin.org\/content\/commentary-roadmap-to-reduce-animal-testing"},{"key":"68883","doi-asserted-by":"crossref","unstructured":"Hansell, L. and Hartung, T. (2026). NAMazing: The importance of being earnest - a 2025 cross-Atlantic turning point in phasing out animal testing. NAM J 2, 100071. doi:10.1016\/j.namjnl.2025.100071","DOI":"10.1016\/j.namjnl.2025.100071"},{"key":"68884","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2013). Look back in anger \u2013 what clinical studies tell us about preclinical work. ALTEX 30, 275-291. doi:10.14573\/altex.2013.3.275","DOI":"10.14573\/altex.2013.3.275"},{"key":"68885","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2024a). The (misleading) role of animal models in drug development. Front Drug Discov 4, 1355044. doi:10.3389\/fddsv.2024.1355044","DOI":"10.3389\/fddsv.2024.1355044"},{"key":"68886","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2024b). The validation of regulatory test methods \u2013 Conceptual, ethical, and philosophical foundations. ALTEX 41, 525-544. doi:10.14573\/altex.2409271","DOI":"10.14573\/altex.2409271"},{"key":"68887","doi-asserted-by":"crossref","unstructured":"Hartung, T. and Tsaioun, K. (2024). Evidence-based approaches in toxicology: Their origins, challenges, and future directions. Evid Based Toxicol 2, 2421187. doi:10.1080\/2833373X.2024.2421187","DOI":"10.1080\/2833373X.2024.2421187"},{"key":"68888","doi-asserted-by":"crossref","unstructured":"Hartung, T., King, N., Kleinstreuer, N. et al. (2024). Leveraging biomarkers and translational medicine for preclinical safety \u2013 Lessons for advancing the validation of alternatives to animal testing. ALTEX 41, 545-566. doi:10.14573\/altex.2410011","DOI":"10.14573\/altex.2410011"},{"key":"68889","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2025). The turning point: April 2025 marks historic shift in US animal testing policy. ALTEX 42, 536-537. doi:10.14573\/altex.2504301","DOI":"10.14573\/altex.2504301"},{"key":"68890","doi-asserted-by":"crossref","unstructured":"Hartung, T. and Smirnova, L. (2025). A path forward \u2013 Advancing microphysiological systems. ALTEX 42, 183-203. doi:10.14573\/altex.2504091","DOI":"10.14573\/altex.2504091"},{"key":"68891","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2026). Pyrogen testing at a turning point \u2013 On occasion of the 30th anniversary of the whole blood monocyte activation test. ALTEX 43, 199-214. doi:10.14573\/altex.2603201","DOI":"10.14573\/altex.2603201"},{"key":"68892","doi-asserted-by":"crossref","unstructured":"Hayashi, K., Sano, M., Kanayasu-Toyoda, T. et al. (2024). Evaluation of the effect of cell freshness on pyrogen detection using a serum-free monocyte-activation test. PLoS One 19, e0316203. doi:10.1371\/journal.pone.0316203","DOI":"10.1371\/journal.pone.0316203"},{"key":"68893","doi-asserted-by":"crossref","unstructured":"He, Q., Yu, C. F., Wu, G. et al. (2024). A novel alternative for pyrogen detection based on a transgenic cell line. Signal Transduct Target Ther 9, 33. doi:10.1038\/s41392-024-01744-0","DOI":"10.1038\/s41392-024-01744-0"},{"key":"68894","doi-asserted-by":"crossref","unstructured":"Herati, R. S. and Wherry, E. J. (2018). What is the predictive value of animal models for vaccine efficacy in humans? Consideration of strategies to improve the value of animal models. Cold Spring Harb Perspect Biol 10, a031583. doi:10.1101\/cshperspect.a031583","DOI":"10.1101\/cshperspect.a031583"},{"key":"68895","doi-asserted-by":"crossref","unstructured":"Heymans, S. and Cooper, L. T. (2022). Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms. Nat Rev Cardiol 19, 75-77. doi:10.1038\/s41569-021-00662-w","DOI":"10.1038\/s41569-021-00662-w"},{"key":"68896","doi-asserted-by":"crossref","unstructured":"Higbee, R. G., Byers, A. M., Dhir, V. et al. (2009). An immunologic model for rapid vaccine assessment \u2013 a clinical trial in a test tube. Altern Lab Anim 37, Suppl 1, 19-27. doi:10.1177\/026119290903701S05","DOI":"10.1177\/026119290903701S05"},{"key":"68897","doi-asserted-by":"crossref","unstructured":"Hoffmann, S., Peterbauer, A., Schindler, S. et al. (2005). International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Meth 298, 161-173. doi:10.1016\/j.jim.2005.01.010","DOI":"10.1016\/j.jim.2005.01.010"},{"key":"68898","doi-asserted-by":"crossref","unstructured":"Jameson, S. C. and Masopust, D. (2018). What is the predictive value of animal models for vaccine efficacy in humans? Reevaluating the potential of mouse models for the human immune system. Cold Spring Harb Perspect Biol 10, a029132. doi:10.1101\/cshperspect.a029132","DOI":"10.1101\/cshperspect.a029132"},{"key":"68899","doi-asserted-by":"crossref","unstructured":"Jeger-Madiot, R., Planas, D., Staropoli, I. et al. (2024). Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting. J Exp Med 221, e20240289. doi:10.1084\/jem.20240289","DOI":"10.1084\/jem.20240289"},{"key":"68900","doi-asserted-by":"crossref","unstructured":"Leist, M., Hasiwa, N., Daneshian, M. et al. (2012). Validation and quality control of replacement alternatives \u2013 Current status and future challenges. Toxicol Res 1, 8-22. doi:10.1039\/C2TX20011B","DOI":"10.1039\/c2tx20011b"},{"key":"68901","doi-asserted-by":"crossref","unstructured":"Leist, M. and Hartung, T. (2013). Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. Arch Toxicol 87, 563-567. doi:10.1007\/s00204-013-1038-0","DOI":"10.1007\/s00204-013-1038-0"},{"key":"68902","doi-asserted-by":"crossref","unstructured":"Leist, M., Ghallab, A., Graepel, R. et al. (2017). Adverse outcome pathways: Opportunities, limitations and open questions. Arch Toxicol 91, 3477-3505. doi:10.1007\/s00204-017-2045-3","DOI":"10.1007\/s00204-017-2045-3"},{"key":"68903","doi-asserted-by":"crossref","unstructured":"Lewis, D. J. M. and Lythgoe, M. P. (2015). Application of \"systems vaccinology\" to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines. J Immunol Res 2015, 909406. doi:10.1155\/2015\/909406","DOI":"10.1155\/2015\/909406"},{"key":"68904","doi-asserted-by":"crossref","unstructured":"Luechtefeld, T., Marsh, D., Rowlands, C. et al. (2018a). Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. Toxicol Sci 165, 198-212. doi:10.1093\/toxsci\/kfy152","DOI":"10.1093\/toxsci\/kfy152"},{"key":"68905","doi-asserted-by":"crossref","unstructured":"Luechtefeld, T., Rowlands, C. and Hartung, T. (2018b). Big-data and machine learning to revamp computational toxicology and its use in risk assessment. Toxicol Res 7, 732-744. doi:10.1039\/C8TX00051D","DOI":"10.1039\/c8tx00051d"},{"key":"68906","doi-asserted-by":"crossref","unstructured":"Lutz, J., Lazzaro, S., Habbeddine, M. et al. (2017). Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29. doi:10.1038\/s41541-017-0032-6","DOI":"10.1038\/s41541-017-0032-6"},{"key":"68907","doi-asserted-by":"crossref","unstructured":"Marshall, L. J., Bailey, J., Cassotta, M. et al. (2023). Poor translatability of biomedical research using animals \u2013 A narrative review. Altern Lab Anim 51, 102-135. doi:10.1177\/02611929231157756","DOI":"10.1177\/02611929231157756"},{"key":"68908","doi-asserted-by":"crossref","unstructured":"Marti\u0107-Kehl, M. I., Schibli, R. and Schubiger, P. A. (2012). Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging 39, 1492-1496. doi:10.1007\/s00259-012-2175-z","DOI":"10.1007\/s00259-012-2175-z"},{"key":"68909","doi-asserted-by":"crossref","unstructured":"Marx, U., Walles, H., Hoffmann, S. et al. (2012). \u2018Human-on-a-chip\u2019 developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257. doi:10.1177\/026119291204000504","DOI":"10.1177\/026119291204000504"},{"key":"68910","doi-asserted-by":"crossref","unstructured":"Marx, U., Beken, S., Chen, Z. et al. (2025). Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare. ALTEX 42, 204-223. doi:10.14573\/altex.2410112","DOI":"10.14573\/altex.2410112"},{"key":"68911","doi-asserted-by":"crossref","unstructured":"Mattei, A. E., Gutierrez, A. H., Seshadri, S. et al. (2024). In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. mAbs 16, 2333729. doi:10.1080\/19420862.2024.2333729","DOI":"10.1080\/19420862.2024.2333729"},{"key":"68912","doi-asserted-by":"crossref","unstructured":"McAdams, D., Estrada, M. R., Holland, D. A. et al. (2022). Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency. Vaccine 40, 5069-5078. doi:10.1016\/j.vaccine.2022.07.017","DOI":"10.1016\/j.vaccine.2022.07.017"},{"key":"68913","doi-asserted-by":"crossref","unstructured":"Meigs, L., Smirnova, L., Rovida, C. et al. (2018). Animal testing and its alternatives \u2013 The most important omics is economics. ALTEX 35, 275-305. doi:10.14573\/altex.1807041","DOI":"10.14573\/altex.1807041"},{"key":"68914","doi-asserted-by":"crossref","unstructured":"Mestas, J. and Hughes, C. C. W. (2004). Of mice and not men: Differences between mouse and human immunology. J Immunol 172, 2731-2738. doi:10.4049\/jimmunol.172.5.2731","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"68915","doi-asserted-by":"crossref","unstructured":"Ming, M., Caterini, J., Ettorre, L. et al. (2020). Replacing the in vivo toxin challenge test with an in vitro assay for assessment of potency for diphtheria toxoid containing vaccines. Biologicals 68, 19-25. doi:10.1016\/j.biologicals.2020.09.003","DOI":"10.1016\/j.biologicals.2020.09.003"},{"key":"68916","doi-asserted-by":"crossref","unstructured":"Mizukami, T., Momose, H., Kuramitsu, M. et al. (2014). System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test. PLoS One 9, e101835. doi:10.1371\/journal.pone.0101835","DOI":"10.1371\/journal.pone.0101835"},{"key":"68917","doi-asserted-by":"crossref","unstructured":"Mizuno, Y., Nakasone, W., Nakamura, M. and Otaki, J. M. (2024). In silico and in vitro evaluation of the molecular mimicry of the SARS-CoV-2 spike protein by common short constituent sequences in the human proteome: Toward safer epitope design for vaccine development. Vaccines 12, 539. doi:10.3390\/vaccines12050539","DOI":"10.3390\/vaccines12050539"},{"key":"68918","doi-asserted-by":"crossref","unstructured":"Molenaar-de Backer, M. W. A., Doodeman, P., Rezai, F. et al. (2023). In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines. Sci Rep 13, 12675. doi:10.1038\/s41598-023-39908-7","DOI":"10.1038\/s41598-023-39908-7"},{"key":"68919","doi-asserted-by":"crossref","unstructured":"Momose, H., Mizukami, T., Ochiai, M. et al. (2010). A new method for the evaluation of vaccine safety based on comprehensive gene expression analysis. J Biomed Biotechnol 2010, 361841. doi:10.1155\/2010\/361841","DOI":"10.1155\/2010\/361841"},{"key":"68920","doi-asserted-by":"crossref","unstructured":"OECD (2005). Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. OECD Series on Testing and Assessment No. 34. OECD Publishing, Paris. doi:10.1787\/e1f1244b-en","DOI":"10.1787\/e1f1244b-en"},{"key":"68921","doi-asserted-by":"crossref","unstructured":"OECD (2025). Guidance Document on Good In Vitro Method Practices (GIVIMP). Second Edition. OECD Series on Testing and Assessment, No. 286. OECD Publishing, Paris. doi:10.1787\/5ba6777b-en","DOI":"10.1787\/5ba6777b-en"},{"key":"68922","doi-asserted-by":"crossref","unstructured":"Pamies, D., Leist, M., Coecke, S. et al. (2022). Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). ALTEX 39, 30-70. doi:10.14573\/altex.2111011","DOI":"10.14573\/altex.2111011"},{"key":"68923","doi-asserted-by":"crossref","unstructured":"Petsch, B., Schnee, M., Vogel, A. B. et al. (2012). Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30, 1210-1216. doi:10.1038\/nbt.2436","DOI":"10.1038\/nbt.2436"},{"key":"68924","doi-asserted-by":"crossref","unstructured":"Pichon, S., Guinet-Morlot, F., Saleh, J. et al. (2023). Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults. Hum Vaccin Immunother 19, 2275453. doi:10.1080\/21645515.2023.2275453","DOI":"10.1080\/21645515.2023.2275453"},{"key":"68925","doi-asserted-by":"crossref","unstructured":"Pinho-Ribeiro, F. A., Verri, W. A. Jr and Chiu, I. M. (2017). Nociceptor sensory neuron-immune interactions in pain and inflammation. Trends Immunol 38, 5-19. doi:10.1016\/j.it.2016.10.001","DOI":"10.1016\/j.it.2016.10.001"},{"key":"68926","doi-asserted-by":"crossref","unstructured":"Prior, H., Adedeji, A. O., Allen, R. et al. (2025). Microsampling in toxicology studies \u2013 Maximising the scientific, business and 3Rs advantages. Toxicol Res (Camb) 14, tfaf045. doi:10.1093\/toxres\/tfaf045","DOI":"10.1093\/toxres\/tfaf045"},{"key":"68927","doi-asserted-by":"crossref","unstructured":"Pullen, R. H. 3rd, Sassano, E., Agrawal, P. et al. (2024). A predictive model of vaccine reactogenicity using data from an in vitro human innate immunity assay system. J Immunol 212, 904-916. doi:10.4049\/jimmunol.2300185","DOI":"10.4049\/jimmunol.2300185"},{"key":"68928","doi-asserted-by":"crossref","unstructured":"Rauch, S., Roth, N., Schwendt, K. et al. (2021). mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines 6, 57. doi:10.1038\/s41541-021-00311-w","DOI":"10.1038\/s41541-021-00311-w"},{"key":"68929","doi-asserted-by":"crossref","unstructured":"Reynaud, K., Atwell, S., V\u00e9drine, C. et al. (2025). Innovative microphysiological systems for vaccine development. Hum Vaccin Immunother 21, 2518641. doi:10.1080\/21645515.2025.2518641","DOI":"10.1080\/21645515.2025.2518641"},{"key":"68930","doi-asserted-by":"crossref","unstructured":"Rohde, C. M., Destexhe, E., van der Laan, J. W. et al. (2025). Are repeat-dose toxicity studies informative for safety assessment of vaccine candidates? A survey of vaccine developers. Int J Toxicol 44, 3-11. doi:10.1177\/10915818241293371","DOI":"10.1177\/10915818241293371"},{"key":"68931","doi-asserted-by":"crossref","unstructured":"Roth, A. and MPS-WS Berlin 2019 (Marx, U., Vil\u00e9n, L., Ewart, L. et al.) (2021). Human microphysiological systems for drug development. Science 373, 1304-1306. doi:10.1126\/science.abc3734","DOI":"10.1126\/science.abc3734"},{"key":"68932","doi-asserted-by":"crossref","unstructured":"Saldanha, L. F., Langel, \u00dc. and Vale, N. (2023). In silico studies to support vaccine development. Pharmaceutics 15, 654. doi:10.3390\/pharmaceutics15020654","DOI":"10.3390\/pharmaceutics15020654"},{"key":"68933","doi-asserted-by":"crossref","unstructured":"Schiffelers, M.-J. W. A., Blaauboer, B. J., Bakker, W. E. et al. (2014). Regulatory acceptance and use of 3R models for pharmaceuticals and chemicals: Expert opinions on the state of affairs and the way forward. Regul Toxicol Pharmacol 69, 41-48. doi:10.1016\/j.yrtph.2014.02.007","DOI":"10.1016\/j.yrtph.2014.02.007"},{"key":"68934","doi-asserted-by":"crossref","unstructured":"Schindler, S., Spreitzer, I., L\u00f6schner, B. et al. (2006). International validation of pyrogen tests based on cryopreserved human primary blood cells. J Immunol Meth 316, 42-51. doi:10.1016\/j.jim.2006.07.023","DOI":"10.1016\/j.jim.2006.07.023"},{"key":"68935","doi-asserted-by":"crossref","unstructured":"Schultz, N. H., S\u00f8rvoll, I. H., Michelsen, A. E. et al. (2021). Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384, 2124-2130. doi:10.1056\/NEJMoa2104882","DOI":"10.1056\/NEJMoa2104882"},{"key":"68936","doi-asserted-by":"crossref","unstructured":"Sellers, R. S. (2017). Translating mouse models: Immune variation and efficacy testing. Toxicol Pathol 45, 134-145. doi:10.1177\/0192623316675767","DOI":"10.1177\/0192623316675767"},{"key":"68937","doi-asserted-by":"crossref","unstructured":"Seok, J., Warren, H. S., Cuenca, A. G. et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110, 3507-3512. doi:10.1073\/pnas.1222878110","DOI":"10.1073\/pnas.1222878110"},{"key":"68938","doi-asserted-by":"crossref","unstructured":"Shao, J., Gao, F., Lin, H. J. et al. (2016). Short-fragment DNA residue from vaccine purification processes promotes immune response to the new inactivated EV71 vaccine by upregulating TLR9 mRNA. PLoS One 11, e0153867. doi:10.1371\/journal.pone.0153867","DOI":"10.1371\/journal.pone.0153867"},{"key":"68939","doi-asserted-by":"crossref","unstructured":"Sharma, V. and McNeill, J. H. (2009). To scale or not to scale: The principles of dose extrapolation. Br J Pharmacol 157, 907-921. doi:10.1111\/j.1476-5381.2009.00267.x","DOI":"10.1111\/j.1476-5381.2009.00267.x"},{"key":"68940","doi-asserted-by":"crossref","unstructured":"Signorazzi, A., Etna, M. P., Coccia, E. M. et al. (2021). In vitro assessment of tick-borne encephalitis vaccine: Suitable human cell platforms and potential biomarkers. ALTEX 38, 431-441. doi:10.14573\/altex.2010081","DOI":"10.14573\/altex.2010081"},{"key":"68941","unstructured":"Spreitzer, I. (2017). Advanced pyrogen testing. American Pharmaceutical Review 20, 32-37."},{"key":"68942","doi-asserted-by":"crossref","unstructured":"Srinivasan, R. and Desert, P. (2026). New approach methodologies in non-clinical safety assessment of vaccines. NAM J 2, 100087. doi:10.1016\/j.namjnl.2026.100087","DOI":"10.1016\/j.namjnl.2026.100087"},{"key":"68943","doi-asserted-by":"crossref","unstructured":"Steger-Hartmann, T., Kreuchwig, A., Vaas, L. et al. (2020). Introducing the concept of virtual control groups into preclinical toxicology testing. ALTEX 37, 343-349. doi:10.14573\/altex.2001311","DOI":"10.14573\/altex.2001311"},{"key":"68944","doi-asserted-by":"crossref","unstructured":"Studholme, L., Sutherland, J., Desai, T. et al. (2019). Evaluation of the monocyte activation test for the safety testing of meningococcal B vaccine Bexsero: A collaborative study. Vaccine 37, 3761-3769. doi:10.1016\/j.vaccine.2018.05.073","DOI":"10.1016\/j.vaccine.2018.05.073"},{"key":"68945","doi-asserted-by":"crossref","unstructured":"Teufel, C., Schlemmer, A.-S., Eiken, A. W. et al. (2026). Lymphoid-tissue-on-chip recapitulates human antibody responses in vitro. Adv Sci 13, e21007. doi:10.1002\/advs.202521007","DOI":"10.1002\/advs.202521007"},{"key":"68946","doi-asserted-by":"crossref","unstructured":"Toinon, A., Moreno, N., Chausse, H. et al. (2019). Potency test to discriminate between differentially over-inactivated rabies vaccines: Agreement between the NIH assay and a G-protein based ELISA. Biologicals 60, 49-54. doi:10.1016\/j.biologicals.2019.05.004","DOI":"10.1016\/j.biologicals.2019.05.004"},{"key":"68947","doi-asserted-by":"crossref","unstructured":"Valentini, S., Santoro, G., Baffetta, F. et al. (2019). Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations. Vaccine 37, 3754-3760. doi:10.1016\/j.vaccine.2018.10.082","DOI":"10.1016\/j.vaccine.2018.10.082"},{"key":"68948","doi-asserted-by":"crossref","unstructured":"van den Biggelaar, R. H. G. A., Hoefnagel, M. H. N., Vandebriel, R. J. et al. (2021). Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Rev Vaccines 20, 1221-1233. doi:10.1080\/14760584.2021.1977628","DOI":"10.1080\/14760584.2021.1977628"},{"key":"68949","doi-asserted-by":"crossref","unstructured":"van der Worp, H. B., Howells, D. W., Sena, E. S. et al. (2010). Can animal models of disease reliably inform human studies? PLoS Med 7, e1000245. doi:10.1371\/journal.pmed.1000245","DOI":"10.1371\/journal.pmed.1000245"},{"key":"68950","doi-asserted-by":"crossref","unstructured":"Van Norman, G. A. (2019). Limitations of animal studies for predicting toxicity in clinical trials: Is it time to rethink our current approach? JACC Basic Transl Sci 4, 845-854. doi:10.1016\/j.jacbts.2019.10.008","DOI":"10.1016\/j.jacbts.2019.10.008"},{"key":"68951","doi-asserted-by":"crossref","unstructured":"Vinken, M. (2013). The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 312, 158-165. doi:10.1016\/j.tox.2013.08.011","DOI":"10.1016\/j.tox.2013.08.011"},{"key":"68952","doi-asserted-by":"crossref","unstructured":"Vipond, C., Findlay, L., Feavers, I. et al. (2016). Limitations of the rabbit pyrogen test for assessing meningococcal OMV-based vaccines. ALTEX 33, 47-53. doi:10.14573\/altex.1509291","DOI":"10.14573\/altex.1509291"},{"key":"68953","doi-asserted-by":"crossref","unstructured":"Vipond, C., Sutherland, J., Nordgren, K. et al. (2019). Development and validation of a monocyte activation test for the control\/safety testing of an OMV-based meningococcal B vaccine. Vaccine 37, 3747-3753. doi:10.1016\/j.vaccine.2018.06.038","DOI":"10.1016\/j.vaccine.2018.06.038"},{"key":"68954","doi-asserted-by":"crossref","unstructured":"von Aulock, S., Busquet, F., Locke, P. et al. (2022). Engagement of scientists with the public and policymakers to promote alternative methods. ALTEX 39, 543-559. doi:10.14573\/altex.2209261","DOI":"10.14573\/altex.2209261"},{"key":"68955","unstructured":"WHO (2005). Guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series No. 927, Annex 1. World Health Organization, Geneva."},{"key":"68956","unstructured":"WHO (2014). Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines. Adopted by the 64th meeting of the WHO Expert Committee on Biological Standardization, 21-25 October 2013. In: WHO Expert Committee on Biological Standardization: Sixty-fourth report. World Health Organization, Geneva, 2014 (WHO Technical Report Series, No. 987), Annex 2."},{"key":"68957","unstructured":"WHO (2025). Guidelines on the Replacement or Removal of Animal Tests for the Quality Control of Biological Products. Adopted by the WHO Expert Committee on Biological Standardization, 81st meeting, October 2025. World Health Organization, Geneva. https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-replacement-of-animal-tests-for-quality-control"},{"key":"68958","doi-asserted-by":"crossref","unstructured":"Williams, K. L. (ed.) (2019). Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems. Cham, Switzerland: Springer Nature. (See Chapter 14: \u201cMonocyte Activation Test\u201d).","DOI":"10.1007\/978-3-030-17148-3"},{"key":"68959","doi-asserted-by":"crossref","unstructured":"Yi, S., Xu, J., Song, L. et al. (2025). Advancing pyrogen testing for vaccines with inherent pyrogenicity: Development of a novel reporter cell-based monocyte activation test (MAT). Vaccines 13, 1009. doi:10.3390\/vaccines13101009","DOI":"10.3390\/vaccines13101009"},{"key":"68960","doi-asserted-by":"crossref","unstructured":"Zhang, B., Korolj, A., Lai, B. F. L. et al. (2018). Advances in organ-on-a-chip engineering. Nat Rev Mater 3, 257-278. doi:10.1038\/s41578-018-0034-7","DOI":"10.1038\/s41578-018-0034-7"},{"key":"68961","doi-asserted-by":"crossref","unstructured":"Zhang, M., Van, L. and Amiji, M. M. (2025). Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review. Mol Ther Nucleic Acids 36, 102686. doi:10.1016\/j.omtn.2025.102686","DOI":"10.1016\/j.omtn.2025.102686"},{"key":"68962","doi-asserted-by":"crossref","unstructured":"Zhou, J., Rao, R., Shapiro, M. E. et al. (2025). Model-informed drug development applications and opportunities in mRNA-LNP therapeutics. Clin Pharmacol Ther 118, 1329-1339. doi:10.1002\/cpt.3641","DOI":"10.1002\/cpt.3641"}],"container-title":["ALTEX - Alternatives to Animal Experimentation"],"original-title":[],"link":[{"URL":"https:\/\/www.altex.org\/index.php\/altex\/article\/download\/3206\/3049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.altex.org\/index.php\/altex\/article\/download\/3206\/3049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:05:59Z","timestamp":1791878759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.altex.org\/index.php\/altex\/article\/view\/3206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":117,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.14573\/altex.2608271","relation":{},"ISSN":["1868-8551","1868-596X"],"issn-type":[{"value":"1868-8551","type":"electronic"},{"value":"1868-596X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}